Mechanism of ophiopogonin D in treatment of pulmonary fibrosis based on network pharmacology and experimental verification
- Author:
Wen-Pan PENG
1
;
Yun-Hai ZHOU
1
;
Juan -Man WU
1
;
Gui-Qing PENG
1
;
Yan-Lan GU
1
;
Song YU
1
;
Ming-Zhi PU
1
;
Yong XU
2
Author Information
- Publication Type:Journal Article
- Keywords: bleomycin; mitophagy; network pharmacology; ophiopogonin D; PINK1/Parkin; pulmonary fibrosis
- From: Chinese Pharmacological Bulletin 2023;39(8):1557-1565
- CountryChina
- Language:Chinese
- Abstract: Aim To predict the potential mechanism of ophiopogonin D (OPD) against pulmonary fibrosis by network pharmacology, and further verify it by experiment in vivo. Methods This study found that ophiopogon was the most frequently used drug in the treatment of pulmonary fibrosis with deficiency of Qi and Yin through data mining. In order to explore its material basis, network pharmacology analysis was carried out. A model of pulmonary fibrosis was established by bleomycin, and different concentrations of ophiopogonin D were administered to verify the results of the pharmacological network. Results Firstly, through network pharmacology analysis, it was found that mitophagy might be the potential target for ophiopogon to exert anti-pulmonary fibrosis effect. Meanwhile, network topology analysis showed that OPD had the greatest relationship with mitophagy. Animal experiments showed that OPD could relieve pulmonary fibrosis and reduce collagen deposition in mice. At the same time, the detection of mitophagy related proteins showed that the compound could increase the expression of PINK1 and Parkin proteins, reduce the content of P62 protein in lung tissue, and reduce the intracellular ROS level. Conclusions OPD can improve mitochondrial function and play an anti-pulmonary fibrosis role by promoting PINKl/Parkin dependent mitophagy in lung tissue.
